IP Library Granted Patent US 10,980,992
Granted Patent B2
US 10,980,992 · App. 15/999,770 · Granted Apr 20, 2021

Methods and compositions related to physiologically responsive microneedle delivery systems

Inventors: Zhen Gu (Raleigh, NC); Yanqi Ye (Raleigh, NC)
Assignee: North Carolina State University
A61M37/0015A61K9/0021A61K38/28A61K38/44A61K38/47A61K47/36A61M37/00C12N5/0677C12Y101/03004C12Y302/01001C12Y302/01003A61M2037/0023A61M2037/0053A61M2202/07A61M2230/201
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,980,992
App. No.
15/999,770
Granted
Apr 20, 2021
Kind
B2
Abstract

Disclosed herein are microneedle devices, kits comprising the microneedle devices, and methods of using the microneedle devices. Specifically, disclosed is a device for transport of a material across a biological barrier of a subject comprising: a plurality of microneedles each having a base end and a tip, with at least one pathway disposed at or between the base end and the tip; a substrate to which the base ends of the microneedles are attached or integrated; and at least one reservoir which is in connection with the base ends of the microneedles array, wherein the reservoir comprises an agent delivery system, wherein the agent delivery system comprises an agent to be transported across the biological barrier, or a means for producing an agent to be transported across the biological barrier, and a means for detecting a physiological signal from the recipient.

Claims (20)

1. A device for transport of a material across a biological barrier of a subject comprising:

a plurality of microneedles each having a base end and a tip, with at least one pathway disposed at or between the base end and the tip;

a substrate to which the base ends of the microneedles are attached or integrated;

at least one reservoir which is in connection with the base ends of the microneedles array, wherein the reservoir comprises an agent delivery system, wherein the agent delivery system comprises an agent to be transported across the biological barrier, or a means for producing an agent to be transported across the biological barrier, and a means for detecting a physiological signal from the recipient, wherein said means for producing an agent to be transported across the biological barrier and said means for detecting a physiological signal both comprise viable, cultured cells; and

a signal amplifier system integrated within the microneedles, wherein the signal amplifier system comprises a component capable of amplifying the physiological signal from the recipient wherein the means for producing an agent to be transported across the biological barrier produces an agent, or changes the amount of agent produced, based on an amplified signal from the signal amplifier system.

2. The device of claim 1 , wherein the agent delivery system comprises a feedback component, such that volume or amount of the agent to be transported across the biological barrier can be altered based on the physiological signal.

3. The device of claim 2 , wherein the physiological signal from the recipient is insufficient to be detected by the feedback component without amplification from the signal amplifier system.

4. The device of claim 1 , wherein the cells are pancreatic β cells or stem cell-differentiated human pancreatic cells.

5. The device of claim 1 , wherein the reservoir is semi-permeable.

6. The device of claim 1 , wherein the reservoir comprises an alginate microgel.

7. The device of claim 1 , wherein the reservoir comprises a therapeutic, prophylactic, or diagnostic agent.

8. The device of claim 7 , wherein the agent is selected from the group consisting of peptides, proteins, carbohydrates, nucleic acid molecules, lipids, organic molecules, biologically active inorganic molecules, and combinations thereof.

9. The device of claim 8 , wherein the agent is insulin.

10. The device of claim 7 , wherein the biological substance is glucose.

11. The device of claim 1 , wherein the physiological signal is a biological substance in the subject.

12. The device of claim 11 , wherein the physiological response in the subject comprises physiological environment factors, including pH, temperature, blood glucose levels and other biomarkers.

13. The device of claim 1 , wherein the signal amplifier system comprises self-assembled polymeric nanosized vesicles.

14. The device of claim 13 , wherein the glucose signal amplifier comprises glucose oxidase, α-amylase, and glucoamylase.

15. The device of claim 1 , wherein the signal amplifier system is in the tip of the microneedle.

16. The method of claim 1 , wherein said viable, cultured cells are mammalian cells.

Assignments (2)
CONFIRMATORY LICENSE Recorded Jul 20, 2023
From: NORTH CAROLINA STATE UNIVERSITY RALEIGH
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 064354/0136 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 17, 2021
From: GU, ZHEN; YE, YANGI
To: NORTH CAROLINA STATE UNIVERSITY
Reel/Frame 055624/0386 →
Continuity (2)
Provisional Application 62297346 · Feb 19, 2016
Related Publication 20190160272A1 · May 30, 2019
Cited By (2)
US 12,186,515 US 12,714,838